Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

NeuroOne Medical Technologies Corporation Registered Shs Aktie 110904763 / US64130M2098

19.11.2025 14:35:42

EQS-News: NeuroOne(R) Announces Upcoming Industry Conference Participation

EQS-News: NeuroOne Medical Technologies / Key word(s): Healthcare
NeuroOne(R) Announces Upcoming Industry Conference Participation

19.11.2025 / 14:35 CET/CEST
The issuer is solely responsible for the content of this announcement.


EDEN PRAIRIE, MINN. - November 19, 2025 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its participation in the following medical industry conferences:

  • American Epilepsy Society (AES) 2025 Annual Meeting in Atlanta, GA between December 5th - December 9th. The Conference website can be found here: AES Annual Meeting Registration

The AES Annual Meeting brings together healthcare providers, scientists, advocates, industry, and other professionals dedicated to better outcomes for people with epilepsy.

Join 100+ industry experts spanning neuroscientists, chemists, device engineers, conjugation scientists, DMPK experts, delivery specialists, and more at the 7th CNS Drug Delivery Summit to collaborate, network, and learn cutting-edge strategies that are tackling the unique challenges in gaining access to the brain.

About NeuroOne

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, monitoring, ablation, drug delivery and stimulation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.

IR Contact
MZ Group – MZ North America
NMTC@mzgroup.us

 

View the original release on www.newmediawire.com


News Source: NeuroOne Medical Technologies


19.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: NeuroOne Medical Technologies
United States
ISIN: US64130M2098
EQS News ID: 2232754

 
End of News EQS News Service

2232754  19.11.2025 CET/CEST

Analysen zu NeuroOne Medical Technologies Corporation Registered Shs

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

3 Knaller-Aktien im BX Musterportfolio📈: Applied Materials, Howmet Aerospace & KLA-Tencor mit François Bloch

Im BX Morningcall werden folgende Aktien analysiert und erklärt
✅ Applied Materials
✅ Howmet Aerospace
✅ KLA-Tencor

👉🏽 https://bxplus.ch/bx-musterportfolio/

3 Knaller-Aktien im BX Musterportfolio📈: Applied Materials, Howmet Aerospace & KLA-Tencor mit François Bloch

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 13’091.21 19.81 SFGBRU
Short 13’375.34 13.57 NTUBSU
Short 13’854.18 8.92 STAB1U
SMI-Kurs: 12’530.62 19.11.2025 17:30:04
Long 12’062.35 19.20 SZEBLU
Long 11’788.62 13.57 SQOB2U
Long 11’296.39 8.92 B1PS3U
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com